COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu
Trial record 27 of 187 for:    GLYCOPYRROLATE

Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03116997
Recruitment Status : Active, not recruiting
First Posted : April 17, 2017
Last Update Posted : April 3, 2020
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Brief Summary:
The purpose of this study is to compare two different medications (neostigmine/glycopyrrolate and sugammadex) to see if one drug improves patient comfort regarding the return of muscle strength after surgery.

Condition or disease Intervention/treatment Phase
Surgery Drug: Neostigmine+glycopyrrolate Drug: Sugammadex Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 201 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized Controlled Assessor Blinded Clinical Trial of Sugammadex Versus Neostigmine /Glycopyrrolate for Reversal of Rocuronium Induced Neuromuscular Blockade: Time to Discharge From Post Anesthesia Care Unit and Patient Satisfaction With Recovery
Actual Study Start Date : April 7, 2017
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : April 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Neuromuscular blockade reversed with neostigmine/gly Drug: Neostigmine+glycopyrrolate
At the conclusion of surgery neuromuscular blockade reversed with neostigmine/glycopyrrolate

Active Comparator: Neuromuscular blockade reversed with sugammadex Drug: Sugammadex
At the conclusion of surgery neuromuscular blockade reversed with sugammadex

Primary Outcome Measures :
  1. Measure Participants' Recovery Time Post-Surgery [ Time Frame: 1 day ]
    Determine whether SUG, as compared to NEO decreases time for patients to be ready for discharge from the PACU post-surgery.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients age 18 years of age or greater who are capable of giving consent
  • Undergoing surgical procedures of expected length 6 </= hours requiring NMB

Exclusion Criteria:

  • Pregnancy
  • History of documented anaphylaxis or contraindication to any of the study medications
  • Active coronary disease with a positive cardiac stress test
  • History of severe chronic obstructive pulmonary disease (COPD) defined as an FEV1 < 50% of predicted
  • Serum Creatinine >/= 2.0 mg/dL
  • Severe hepatic dysfunction accompanied by coagulopathy

    • Definition:
    • Known liver Disease AND
    • INR > 1.5 (except for patients on anticoagulants) AND
    • Platelet count <100,00/ul without other obvious cause
  • Chronic sustained release opioid for > 2 weeks duration pre op (in the 30 days prior to surgery)
  • Use of toremifene
  • Significant cognitive impairment or documented psychologic impairment
  • Myasthenia gravis or other neuromuscular disease
  • Patients who are not eligible for standard anesthetic induction, eg, those needing rapid sequence induction or awake fiberoptic bronchial intubation.
  • American Society of Anesthesiologists (ASA) Status > 3

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03116997

Layout table for location information
United States, New Jersey
Memoral Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States, 07920
United States, New York
Memorial Sloan Kettering Commack
Commack, New York, United States, 11725
Memoral Sloan Kettering Westchester
Harrison, New York, United States, 10604
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Layout table for investigator information
Principal Investigator: German Echeverry, MD Memorial Sloan Kettering Cancer Center
Additional Information:
Layout table for additonal information
Responsible Party: Memorial Sloan Kettering Cancer Center Identifier: NCT03116997    
Other Study ID Numbers: 17-207
First Posted: April 17, 2017    Key Record Dates
Last Update Posted: April 3, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Memorial Sloan Kettering Cancer Center:
neuromuscular blockade
Additional relevant MeSH terms:
Layout table for MeSH terms
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Adjuvants, Anesthesia
Muscarinic Antagonists
Cholinergic Antagonists